Pharmaceutical Forum - The three years process
Pharmaceutical Forum plenary meetings, 2006 and 2007
Commission Vice-President Günter Verheugen and Commissioner Markos Kyprianou co-chaired the ministerial level Pharmaceutical Forum on 29 September 2006 in Brussels. The meeting was attended by national health ministers, MEPs and various stakeholders.The first Forum meeting discussed the issues dealt with by the three Working Groups that has been established: Improving information on medicines to patients, finding a balance between rewarding innovation, value for money and access to medicines in pricing and reimbursement policies, and quicker access to effective medicines through relative effectiveness policies.Following the discussions, the Forum adopted the Progress Report and its conclusions. These conclusions provide a direction for the future work within the Working Groups.
Pharmaceutical Forum First Progress Report [54 KB] , 29 September 2006
- Speech of Commissioner Kyprianou
- Speech of Vice-President Verheugen
- Press release
The second Forum was held on 26 June 2007. Commission Vice-President Günter Verheugen and Commissioner Markos Kyprianou co-chaired the second ministerial-level Pharmaceutical Forum in Brussels. The meeting was attended by Health Ministers of Member States, MEPs and senior representatives from the Forum's ten stakeholder organisations.
This second Forum meeting acknowledged the work undertaken by the three working groups on Relative Effectiveness, Pricing and Reimbursement, and Information to Patients. There was widespread recognition of the challenges that each one was facing but acknowledgement that there had been some progress in all three. The Forum adopted a progress report which summarised the work of each of the working groups and set out objectives for the forthcoming year.
- Pharmaceutical Forum Second Progress Report [90 KB] , 26 June 2007
- Joint ESIP and AIM Position Statement on Information to Patients on Diseases and Treatment Options [11 KB] , 26 June 2007
The Steering Committee prepared the annual Pharmaceutical Forum and oversaw the work of, and provided the operational guidance to, the Working Groups. It was also responsible for ensuring the flow of information between the Pharmaceutical Forum and Working Groups. To ensure the effectiveness of the Committee the membership was restricted to 7 Member States (selected from recent, current and upcoming Presidencies), representation of the European Parliament, and a senior representative from ten key stakeholder organisations. The Committee was chaired jointly by DG Enterprise and Industry and by DG Health and Consumer Protection.
Three expert Working Groups supported the work of the Forum and the Steering Committee. The task of the Working Groups was to consider how to make progress on information to patients, pricing policies and relative effectiveness assessments. The role of the Working Groups was to provide expert advice on information to patients, pricing and relative effectiveness. The Working Groups were composed of representatives of the Member States and the stakeholders. Working Groups were chaired jointly by DG Enterprise and Industry and by DG Health and Consumer Protection.public consultation on the work of the Information to Patient Working Group. The objective of this public consultation was twofold. Firstly, the aim was to disseminate information on the work and proposals of the working group on information to patients established under the Pharmaceutical Forum. Secondly, it provided an opportunity for all relevant stakeholders to give their views and comments on the output of the working group.
- Responses of the Public consultation on Health-related information to patients
- Summary report of the consultation
- Related documents